Is increased D2 receptor availability associated with response to stimulant medication in ADHD

Area of Science:

• Neuroscience
• Radiology
• Pharmacology

Background:

• Attention-deficit-hyperactivity disorder (ADHD) is a common neurodevelopmental disorder.
• Dopamine D2 receptors in the striatum are implicated in ADHD pathophysiology.
• Previous studies suggest altered dopamine receptor availability in ADHD, but data in non-drug-treated children is limited.

Purpose of the Study:

• To estimate striatal dopamine D2 receptor availability in children with ADHD before and after methylphenidate therapy.
• To examine correlations between symptom severity, treatment response, and D2 receptor binding levels.

Main Methods:

• Nine children with ADHD underwent brain SPECT imaging using 123I IBZM before and after 3 months of methylphenidate treatment.
• Semiquantitative analysis was used to determine D2 receptor binding ratios in the basal ganglia.
• Symptom severity was assessed using hyperactivity scores and Conners Teacher Rating Scale.

Main Results:

• Children with ADHD exhibited higher baseline striatal D2 receptor availability compared to healthy adults.
• Methylphenidate therapy significantly reduced D2 availability in the striatum (p<0.05).
• Higher baseline D2 receptor levels correlated with a greater reduction in hyperactivity and Conners scores, indicating better treatment response.

Conclusions:

• Non-drug-treated children with ADHD show elevated striatal D2 receptor availability.
• Methylphenidate down-regulates D2 receptor availability in ADHD, similar to healthy adults.
• Initial D2 receptor availability may predict treatment response to methylphenidate in ADHD.